Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D

Kim, Han Wool; Lee, So‐Young; Kim, Kyung Hyo

doi:10.1097/md.0000000000004854

Cited by 14 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study of elderly adults, post-vaccination IgG antibody concentrations for two serotypes (6B and 19F) of the five studied (4, 6B, 14, 19F, and 23F) were significantly lower and in vitro opsonophagocytosis of all five IgG serotype-specific antibodies was significantly reduced [50]. In two other reports, serotype-specific pre- and post-immune antibody responses measured by opsonophagocytosis were also significantly lower in elderly adults [51, 52]. IgG responses to PPS4 and PPS14 in elderly adults were associated with decreased V H repertoire (mostly V H 3) and somatic mutations and with greater loss of oligoclonality than younger adults [51].…”

Section: Discussionmentioning

confidence: 99%

Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations

Parker¹,

Sköld²,

Harding³

et al. 2019

BMC Immunol

View full text Add to dashboard Cite

Background: We sought to compare Pneumovax®23 responses in adults with subnormal IgG subclass concentrations. We studied adults with normal total IgG, frequent/severe respiratory infection, and subnormal IgG1, IgG3, or IgG1 + IgG3 before and after Pneumovax®23. We defined response as serotype-specific IgG > 1.3 μg/mL and aggregate response as IgG > 1.3 μg/mL for ≥70% of all serotypes tested. We compared patients with and without serotype-specific responses and performed logistic regression on aggregate responses using: age; male sex; body mass index; autoimmune condition(s); atopy; other allergies; subnormal IgGSc immunophenotypes; IgA; and IgM. Results: There were 59 patients (mean age 44 ± 13 (SD) years; 83.1% women). Median days between pre-and post-Pneumovax®23 testing was 33 (range 19-158). The median post-vaccination summated concentration of serotypespecific IgG was higher in patients with subnormal IgG1 than subnormal IgG3 (responders and non-responders). All subnormal IgG1 + IgG3 non-responders responded to serotypes 8, 9 and 26, unlike other non-responders. Subnormal IgG3 responders had lower responses to serotypes 1, 4, 12, 23, 26, and 51. Subnormal IgG3 nonresponders had higher responses to serotypes 1, 3, 8, 9, 12, 14, 19, 51, and 56. Response rates decreased with increasing age. Aggregate responders were: subnormal IgG1, 54%; IgG3, 46%; and IgG1 + IgG3, 46%. Regression on aggregate response revealed lower response with male sex (odds ratio 0.09 [95% CI 0.01, 0.77]) and atopy (0.17 [0.03, 0.83]). Conclusions: Serotype-specific IgG responses to Pneumovax®23 were greater in patients with subnormal IgG1 than subnormal IgG3. Male sex and atopy were associated with lower aggregate responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations

Parker¹,

Sköld²,

Harding³

et al. 2019

BMC Immunol

View full text Add to dashboard Cite

show abstract

“…The serotype-specific VE was estimated for each serotype if its number of isolates was >30. To explore the potential effect of cross-immunity produced by PPSV23 on serogroup 6 ( 23 ), VE of IPD for serotypes 6A, 6B, 6C, and 6D was calculated excluding these serotypes from the controls. VE was stratified by the 2 study phases (2013–2015 and 2016–2017).…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Shimbashi¹,

Suzuki²,

Chang³

et al. 2020

Emerg. Infect. Dis.

View full text Add to dashboard Cite

S treptococcus pneumoniae is a major cause of illness and death among adults (1). Pneumonia is the most common form of pneumococcal disease in adults, whereas invasive pneumococcal disease (IPD), including meningitis and bacteremia, has severe clinical manifestations with a high case-fatality ratio (2). Because incidence of adult IPD is high among older adults, it is a public health concern, particularly in countries with aging populations, such as Japan (3,4). Two types of pneumococcal vaccines are currently available for adults: the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and the 13-valent pneumococcal conjugate vaccine (PCV13). According to a systematic review, the effectiveness of PPSV23 against IPD among adults >50 years of age was 54% (5). The CAPITA trial showed that the efficacy of PCV13 against IPD among adults >65 years of age was 75% (6). Since 2014, both PPSV23 and PCV13 have been recommended for older persons in the United States (7), whereas only PPSV23 is recommended in other high-income countries. Discussions over adult pneumococcal vaccination programs are complicated because of differences in vaccine effectiveness (VE) by serotype and age group. Previous studies have suggested that VE of PPSV23 differs by serotype (8,9), so overall VE might vary on the basis of the distribution of serotypes among the vaccinated population. In many countries, the proportion of PCV-covered serotypes among adult IPD patients has been decreasing since the introduction of pediatric PCVs (10-13); this

show abstract

“…Furthermore, 35 sera from healthy adults (30–50 years old) and 62 sera from the elderly (65–85 years old) were studied after receiving each subject's written informed consent. 12 In the elderly, subjects with pre-existing but stable health conditions (including well controlled diabetes mellitus, cardiovascular disease, pulmonary disease, and liver cirrhosis) were included. However, subjects with immune-compromising conditions such as human immunodeficiency virus (HIV) infection, leukemia, generalized malignancy, chronic renal failure, primary or acquired immunodeficiency, and diseases requiring immunosuppressive-drug treatments were excluded.…”

Section: Methodsmentioning

confidence: 99%

“…However, subjects with immune-compromising conditions such as human immunodeficiency virus (HIV) infection, leukemia, generalized malignancy, chronic renal failure, primary or acquired immunodeficiency, and diseases requiring immunosuppressive-drug treatments were excluded. 12 Collected samples were stored frozen at −70°C until testing. All sera were found to be free from antibiotics based on their inability to inhibit the growth of R36A pneumococcal bacteria, and were incubated at 56°C for 30 minutes to inactivate endogenous complement activity before our opsonophagocytic killing assay (OPA).…”

Section: Methodsmentioning

confidence: 99%

Seroprevalence of Opsonophagocytic Antibodies against Serotype Ia, Ib, II, III, and V Group B Streptococcus among Korean Population

Lee

Kim

2018

J Korean Med Sci

Self Cite

View full text Add to dashboard Cite

BackgroundInvasive Streptococcus agalactiae (group B streptococcus, GBS) infection most commonly occurs in infants; however, cases of GBS infection in adults, particularly in the elderly with significant underlying diseases, are being increasingly reported. We analyzed the serotype specific opsonophagocytic antibodies (the major mechanism of protection against GBS) in infants, adults, and the elderly.MethodsThe opsonization indices (OIs) of antibodies against serotype Ia, Ib, II, III, and V GBS were studied in 89 infants, 35 adults (age, 30–50 years), and 62 elderly individuals (age, 65–85 years) according to the University of Alabama at Birmingham GBS opsonophagocytic killing assay protocol (www.vaccine.uab.edu).ResultsIn infants, adults, and elderly groups respectively, geometric mean of OI against GBS serotype Ia were 3, 7, and 32; against GBS serotype Ib were 7, 242, and 252; against serotype II were 93, 363, and 676; against serotype III were 8, 212, and 609; and against serotype V were 4, 639, and 610. The seropositive rate (% of subjects with OI ≥ 4) increased significantly in older age group for all five serotypes.ConclusionDuring infancy, only a limited proportion of infants have functional immunity against serotype Ia, Ib, II, III, and V GBS. Furthermore, a lack of opsonic activities against GBS observed in some adults and the elderly might predispose such individuals to the risk of invasive GBS infection. Epidemiological monitoring and development of suitable vaccine for these populations are needed.

show abstract

Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D

Cited by 14 publications

References 34 publications

Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations

Pneumococcal vaccination responses in adults with subnormal IgG subclass concentrations

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Seroprevalence of Opsonophagocytic Antibodies against Serotype Ia, Ib, II, III, and V Group B Streptococcus among Korean Population

Contact Info

Product

Resources

About